Építés alatt – nem éles oldal
Belépés
Taking people in Kanada2/3. fázis

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Key facts

Where
North York, Peterborough és Whitby, KanadaSee the 4 sites
Phase
2/3. fázis

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 55 and 90 years old?

Forrás: NCT07284472: ki vehet részt

Where in Kanada

  • Baycrest Centre for Geriatric CareNorth York, KanadaTaking people
  • Sunnybrook Health Sciences CentreNorth York, KanadaTaking people
  • Kawartha CentrePeterborough, KanadaTaking people
  • Ontario Shores Centre for Mental Health SciencesWhitby, KanadaToborzás még nem indult

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Exciva GmbH
Trial code
NCT07284472EU 2024-517388-22-00
Record updated
2026. november 6.
Original description
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.Read full original descriptionShow less

Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants With Alzheimer's Disease Dementia

The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.

Inclusion: The participant is an adult male or female between the ages of 55 to 90 years inclusively, who can move around by themselves, with a walker or a wheelchair; A previously established diagnosis of AD dementia; The participant has clinically significant, moderate/severe agitation at the time of screening and for at least 2 weeks prior to randomization; The diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation; Caregiver who is able and willing to comply with all required study procedures and who is in contact with the participant at least on four individual days for at least two hours per day.

Exclusion: The participant has a confirmed primary diagnosis of a dementia-related disease other than AD dementia; The participant has symptoms of agitation that are not secondary to AD dementia; The participant has a history of uncontrolled seizures or a history of epilepsy; The participant has a major medical illness or unstable medical condition.

ClinicalTrials.gov NCT07284472 · EU CTIS 2024-517388-22-00